mutares confirms excellent operational performance

The mutares Group (ISIN: DE000A0SMSH2) closed the first half of 2015 with significant organic growth in revenues and a clear increase in profitability. Today’s publication of mutares Group’s Interim Report 2015 will be accompanied by a conference call for analysts and investors.

Albeit the deconsolidation of the portfolio companies CGVL and Suir Pharma, mutares has been successful to increase group revenues to a record level of EUR 311.6 m (previous year: EUR 307.5 m). Particularly the organic growth in revenues of EUPEC, STS Acoutistics, Elastomer Solutions, and Geesinknorba contributed to this great performance. The group’s operative result (EBITDA) increased by 24% up to EUR 12.9 m (previous year: EUR 10.4 m). The most important drivers of this development were the portfolio companies EUPEC, STS Acoustics and Elastomer Solutions.

Besides the excellent operational development, the first half of 2015 was characterized by strong M&A activity with four successful transactions. By opening the French subsidiary in Paris, mutares strategically strengthened its M&A activities. With two transactions, the French team has largely contributed to the success of mutares in the first half of 2015.

Given the full transaction pipeline and especially the enhanced focus on portfolio growth by add-on acquisitions, mutares considers its presence at the capital markets as strategically important for the future development of the group. The significant increase of mutares’ share price since the beginning of the year reflects the outstanding performance of the group. With the publication of the NAV, mutares intends to further increase the transparency for investors. Moreover, mutares will hold a conference call today for the first time to present its half year figures 2015.